-transparent.png){kind=logo}
1. The effects of morphine, nalorphine, acetazolamide, and 10% CO(2) on brain metabolite concentrations of 24h-starved rats were studied. 2. A single dose of morphine (20mg/kg body wt.) caused an increase in brain glucose concentration (42%) and decreased concentrations of lactate (24%), pyruvate (29%), citrate (20%), alpha-oxoglutarate (16%), malate (14%) and creatine phosphate (10%) after 30min. No changes were found in adenine nucleotide concentrations. 3. The same dose of morphine increased arterial CO(2) from 5.07 to 7.60 kN/m(2) (38 to 57 Torr), decreased the pH from 7.41 to 7.31 and decreased O(2) from 14.1 to 10.8kN/m(2) (106 to 81 Torr) at 30min. 4. Rats injected with morphine three times daily (20mg/kg body wt.) for 2 weeks had no changes in brain metabolite concentrations or in blood gases 30min after their last injection. 5. Nalorphine (an antagonist of morphine) caused essentially no changes in brain metabolite concentrations in normal rats. When nalorphine (20mg/kg) was administered to rats previously treated with morphine three times daily for 2 weeks, there was an increase in brain glucose (100%), lactate (23%), pyruvate (18%) and citrate (10%) concentrations. 6. Acetazolamide (an inhibitor of carbonic anhydrase) and 10% CO(2) increased the arterial CO(2) from 4.79 to 6.78kN/m(2) (36 to 51 Torr) and from 5.32 to 10.8kN/m(2) (40 to 81 Torr) respectively. 7. Both acetazolamide and 10% CO(2) caused changes in brain metabolite concentrations similar to those for acutely administered morphine. Thus 10% CO(2) caused increased brain glucose concentration (123%) and decreased brain lactate (46%), pyruvate (34%), citrate (26%), alpha-oxoglutarate (33%), malate (45%) and creatine phosphate (7%) concentrations. No changes in adenine nucleotide concentrations were found. 8. The results indicate that the effect of morphine on brain metabolite concentrations may be accounted for by the increased [CO(2)]. 9. These findings constitute a consistent pattern of metabolic changes after acute morphine administration, morphine addiction, and withdrawal from morphine addiction.
A L Miller, and
R A Hawkins, and
R L Harris, and
R L Veech
February 1989,
The Journal of pharmacology and experimental therapeutics,
A L Miller, and
R A Hawkins, and
R L Harris, and
R L Veech
January 1976,
Proceedings of the Western Pharmacology Society,
A L Miller, and
R A Hawkins, and
R L Harris, and
R L Veech
September 1982,
Molecular pharmacology,
A L Miller, and
R A Hawkins, and
R L Harris, and
R L Veech
October 2012,
Neuropeptides,
A L Miller, and
R A Hawkins, and
R L Harris, and
R L Veech
July 1975,
The Journal of pharmacology and experimental therapeutics,
A L Miller, and
R A Hawkins, and
R L Harris, and
R L Veech
October 2002,
Neuropharmacology,
A L Miller, and
R A Hawkins, and
R L Harris, and
R L Veech
December 1959,
Nature,
A L Miller, and
R A Hawkins, and
R L Harris, and
R L Veech
February 2003,
Regulatory peptides,
A L Miller, and
R A Hawkins, and
R L Harris, and
R L Veech
October 2004,
Acta pharmacologica Sinica,
A L Miller, and
R A Hawkins, and
R L Harris, and
R L Veech
December 1974,
Life sciences,
